Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7858122 | UCB INC | Extended release formulation of levetiracetam |
Sep, 2028
(4 years from now) |
Keppra Xr is owned by Ucb Inc.
Keppra Xr contains Levetiracetam.
Keppra Xr has a total of 1 drug patent out of which 0 drug patents have expired.
Keppra Xr was authorised for market use on 12 September, 2008.
Keppra Xr is available in tablet, extended release;oral dosage forms.
The generics of Keppra Xr are possible to be released after 17 September, 2028.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Dosage Form(NDF) | Sep 12, 2011 |
Drugs and Companies using LEVETIRACETAM ingredient
Market Authorisation Date: 12 September, 2008
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL